Skip to main content
SpringerLink
Log in

The Place of Felbamate in the Treatment of Epilepsy

  • Drug Therapy
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Felbamate is one of a new generation of antiepileptic agents that has recently reached the market. In July 1993, it was approved for use in the US as an adjunctive and monotherapy in adults with partial seizures, with or without generalisation, and as adjunctive therapy in children with Lennox-Gastaut syndrome. However, the unexpected development of aplastic anaemia prompted the US Food and Drug Administration and the manufacturer, Carter Wallace, to issue a strong warning on 1 August 1994 regarding continued use of felbamate. Shortly thereafter, reports of felbamate-associated hepatic failure engendered further concern. As a result, felbamate is not indicated as a first-line treatment, but should be used only in those patients who respond inadequately to alternative treatments and whose epilepsy is severe enough that the risk of aplastic anaemia and/or liver failure is deemed acceptable by the patient compared with the benefits conferred by its use. Because of the effectiveness of this drug in many patients, felbamate will remain on the market in the US and may be available in certain situations in other countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity offelbamate and four prototype anti epileptic drugs in mice and rats. Epilepsia 1986; 27: 27–34

    Article  PubMed  CAS  Google Scholar 

  2. White HS, Wolf HH, Swinyard EA, et al. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 1992 May-Jun; 33 (3): 564–72

    Article  PubMed  CAS  Google Scholar 

  3. McCabe RT, Wasterlain CG, Kucharczyk N, et al. Evidence for anticonvulsant and neuroprotectant action offelbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993; 264: 1248–52

    PubMed  CAS  Google Scholar 

  4. Rho JM, Donevan SO, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effect on N-methylD- aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 1994 Feb; 35 (2): 229–34

    Article  PubMed  CAS  Google Scholar 

  5. Ticku MK, Kamatchi GL, Sofia RD. Effect of anticonvulsant felbamate on GABAA receptor system. Epilepsia 1991; 32: 389–91

    Article  PubMed  CAS  Google Scholar 

  6. Yamaguchi S, Rogawski MA. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilep Res 1992; 11: 9–16

    Article  CAS  Google Scholar 

  7. Sofia RD, Gordon R, Gels M, et al. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. Res Commun Chern Pathol Pharmacol 1993; 79: 335–41

    CAS  Google Scholar 

  8. Chronopoulos A, Stafstrom C, Thurber S, et al. Neuroprotective effect of felbamate after kainic acid-induced status epilepticus. Epilepsia 1993 Mar-Apr; 34 (2): 359–66

    Article  PubMed  CAS  Google Scholar 

  9. Gordon R, Gels M, Wichmann J, et al. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia 1993; 34 (2): 367–71

    Article  PubMed  CAS  Google Scholar 

  10. Gordon R, Gels M, Diamantis W, et al. Interaction offelbamate and diazepam against maximal electroshock seizures and chemoconvulsants in mice. Pharmacol Biochem Behav 1991 Sep; 40 (1): 109–13

    Article  PubMed  CAS  Google Scholar 

  11. Wallis RA, Panizzon KL. Glycine reversal offelbamate hypoxic protection. Neuroreport 1993 Jul; 4 (7): 951–4

    Article  PubMed  CAS  Google Scholar 

  12. Wasterlain CG, Adams LM, Hattori H, et al. Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur J Pharmacol 1992 Mar; 212 (2-3): 275–8

    Article  PubMed  CAS  Google Scholar 

  13. Adusumalli VE, Gilchrist JR, Wichmann JK, et al. Pharmacokinetics of felbamate in pediatric and adult beagle dogs. Epilepsia 1992; 33: 955–60

    Article  PubMed  CAS  Google Scholar 

  14. Shumaker RC, Fantel C, Kelton E, Kelton E. Evaluation oftheelimination Of(I4(:) felbamate in healthy men [abstract]. Epilepsia 1990; 31: 642

    Google Scholar 

  15. Gudipati RM, Raymond RH, Ward or, et al. Effect of food on the absorption of felbamate in healthy male volunteers [abstract]. Neurology 1992; 42 Suppl.3: 332

    Google Scholar 

  16. Wilensky AJ, Friel PN, Ojemann LM, et al. Pharmacokinetics ofW-554 (ADD03055) in epileptic patients. Epilepsia 1985; 26: 602–6

    Article  PubMed  CAS  Google Scholar 

  17. Ward DL, Shumaker RD. Comparative bioavailability of felbamate in healthy men [abstract]. Epilepsia 1990; 31: 642

    Google Scholar 

  18. Adusumalli VE, Yang JT, Wong KK, et al. Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metab Dispos 1991; 19: 1116–25

    PubMed  CAS  Google Scholar 

  19. Comford EM, Young D, Paxton JW, et al. Blood-brain barrier penetration offelbamate. Epilepsia 1992 Sep-Oct; 33 (5): 944–54

    Article  Google Scholar 

  20. Adusumalli VE, Yang JT, Wong KK, et al. Felbamate pharmacokinetics in the rat, rabbit and dog. Drug Metabol Distrib 1991; 19: 1116–25

    CAS  Google Scholar 

  21. Adusumalli VE, Wong KK, Kucharczyk N, et al. Felbamate in vitro metabolism by rat liver microsomes. Drug Metab Dispos 1991 Nov-Dec; 19 (6): 1135–8

    PubMed  CAS  Google Scholar 

  22. Yang JT, Adusumalli VE, Wong KK, et al. Felbamate metabolism in the rat, rabbit, and dog. Drug Metab Dispos 1991 Nov-Dec; 19 (6): 1126–34

    PubMed  CAS  Google Scholar 

  23. Yang JT, Morris M, Wong KK, et al. Felbamate metabolism in pediatric and adult beagle dogs. Drug Metab Dispos 1992; 20: 84–8

    PubMed  CAS  Google Scholar 

  24. Adusumalli VE, Choi YM, Romanyshyn LA, et al. Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate. Drug Metab Dispos 1993; 21: 710–6

    PubMed  CAS  Google Scholar 

  25. Miller ML, Holmes GB, Marienau K, et al. Successful withdrawal of phenytoin in refractory patients with epilepsy [abstract]. Neurology 1989; 39: 120

    Google Scholar 

  26. Wagner ML, Graves NM, Marienau K, et al. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991; 32: 398–406

    Article  PubMed  CAS  Google Scholar 

  27. Ward DL, Wagner ML, Perhach JL, et al. Felbamate steadystate pharmacokinetics during coadministration of valproate [abstract]. Epilepsia 1991; 32 Suppl.3: 8

    Google Scholar 

  28. Wagner ML, Leppik IE, Graves NM, et al. Felbamate serum concentrations: effect of valproate, carbamazepine, phenytoin, and phenobarbital [abstract]. Epilepsia 1990; 31: 642

    Google Scholar 

  29. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991 Nov; 41 (11): 1785–9

    Article  PubMed  CAS  Google Scholar 

  30. Theodore WH, Raubertas RF, Porter RJ, et al. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991; 32: 392–7

    Article  PubMed  CAS  Google Scholar 

  31. Leppik IE, Kramer LD, Bourgeoise B, et al. Felbamate after withdrawal from other antiepileptic drugs [abstract]. Neurology 1990; 40: 158

    Article  Google Scholar 

  32. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43: 693–6

    Article  PubMed  CAS  Google Scholar 

  33. Sachdeo R, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992 Sep; 32: 386–92

    Article  PubMed  CAS  Google Scholar 

  34. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993; 43: 688–92

    Article  PubMed  CAS  Google Scholar 

  35. Wolff DL, Kerrick JM, Rarick J, et al. Post-market fe1bamate use in the refractory epilepsy population [abstract]. Epilepsia 1994; 35 (8): 32

    Google Scholar 

  36. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 1993; 328: 29–33

    Article  Google Scholar 

  37. Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34 Suppl.7: S18–24

    Article  PubMed  Google Scholar 

  38. Perhach JL, Weliky I, Newton N, et al. Felbamate. In: Meldrum BS, Porter RJ, editors. New anticonvulsant drugs. London: John Libbey, 1986: 117–23

    Google Scholar 

  39. Felbatol Package Insert, 1994 Oct

  40. Graves N. Felbamate. Ann Pharmacother 1993; 27: 1073–81

    PubMed  CAS  Google Scholar 

  41. Ney GC, Schaul N, Loughlin J, et al. Thrombocytopenia in association with adjunctive felbamate use. Neurology 1994 May; 44 (5): 980–1

    Article  PubMed  CAS  Google Scholar 

  42. FDA Memorandum. Postrnarketing safety evaluator reports evaluation branch, HFD-735. Washington (DC): FDA, 9 Sept 1994

    Google Scholar 

  43. Segelman FH, Kelton E, Terzi RM, et al. The comparative potency of phenobarbital and five 1,3-propanediol dicarbamazates for cytochrome p450 induction in rats. Res Commun Chern Pathol Pharmacol 1985; 48: 467–70

    CAS  Google Scholar 

  44. Swinyard EA, Woodhead JH, Franklin MR, et al. The effect of chronic felbamate administration on anticonvulsant activity and hepatic drug-metabolizing enzymes in mice and rats. Epilepsia 1987; 28: 295–300

    Article  PubMed  CAS  Google Scholar 

  45. Graves NM, Holmes GB, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989; 30: 225–9

    Article  PubMed  CAS  Google Scholar 

  46. Graves NM, Ludden TM, Holmes GB, et al. Pharmacokinetics of felbamate, a novel anti epileptic drug: application of mixedeffect modeling to clinical trials. Pharmacotherapy 1989; 9: 372–6

    PubMed  CAS  Google Scholar 

  47. Fuerst RH, Graves NM, Leppik IE, et al. A preliminary report on alteration of carbamazepine and phenytoin metabolism by felbamate [abstract]. Drug Intell Clin Pharm 1986; 20: 465–6

    Google Scholar 

  48. Fuerst RH, Graves NM, Leppik IE, et al. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia 1988; 29: 488–91

    Article  PubMed  CAS  Google Scholar 

  49. Wagner ML, Remmel RP, Graves NM, et al. Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 1993; 53: 536–43

    Article  PubMed  CAS  Google Scholar 

  50. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991; 32: 130–2

    Article  PubMed  CAS  Google Scholar 

  51. Gidal BE, Zupanc ML. Potential pharmacokinetic interaction between felbamate and phenobarbital. Ann Pharmacother 1994; 28: 455–8

    PubMed  CAS  Google Scholar 

  52. Kerrick JM, Wolff DL, Risinger MW, et al. Increased phenobarbital plasma concentrations after felbamate initiation [abstract]. Epilepsia 1994; 35 (8): 94

    Google Scholar 

  53. Wagner ML, Graves NM, Leppik IE, et al. The effect of fe⋏mate on valproate disposition [abstract]. Epilepsia 1991; 32: 15

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MINCEp® Epilepsy Care, the Department of Neurology and College of Pharmacy, University of Minnesota, 5775 Wayzata Blvd., Suite 255, Minneapolis, Minnesota, 55416-1222, USA

    Ilo E. Leppik

  2. MINCEp® Epilepsy Care and the College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA

    Denise L. Wolff

Authors
  1. Ilo E. Leppik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denise L. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leppik, I.E., Wolff, D.L. The Place of Felbamate in the Treatment of Epilepsy. CNS Drugs 4, 294–301 (1995). https://doi.org/10.2165/00023210-199504040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199504040-00006

Keywords

Search

Navigation